Inhibition of tumour growth and metastasis of human fibrosarcoma cells HT-1080 by monoclonal antibody BCD-F9

Citation
M. Popkov et al., Inhibition of tumour growth and metastasis of human fibrosarcoma cells HT-1080 by monoclonal antibody BCD-F9, EUR J CANC, 37(18), 2001, pp. 2484-2492
Citations number
33
Categorie Soggetti
Oncology,"Onconogenesis & Cancer Research
Journal title
EUROPEAN JOURNAL OF CANCER
ISSN journal
09598049 → ACNP
Volume
37
Issue
18
Year of publication
2001
Pages
2484 - 2492
Database
ISI
SICI code
0959-8049(200112)37:18<2484:IOTGAM>2.0.ZU;2-W
Abstract
BCD-F9 is it marine IgG(2a) monoclonal antibody (mAb) that recognises a con formational epitope found on the surface of many human tumour cells. The ai m of this study was to investigate the ability of BCD-F9 to recognise a var iety of neoplastic cell lines and to test BCD-F9 in vivo for anticancer act ivity in subcutaneous (s.c.) and metastatic tumour models. Intravenous (i.v .) administration of BCD-F9 in CD-I nude mice xenografted s.c. with human H T-1080 cells led to it significant inhibition of tumour growth. We demonstr ated that BCD-F9 administrated i.v. significantly prolonged the life-span o f CD-1 nude mice inoculated i.v. with the same tumour cell line that induce s aggressive lung metastases in the untreated mice. We also investigated th e antitumour activity of BCD-F9 in vitro in antibody-dependent cellular cyt otoxicity (ADCC) and antibody-dependent complement-mediated cytotoxicity (A DCMC) assays. The effector cell subpopulations were obtained by macrophage stimulation (thioglycollate) or natural killer (NK) cell enrichment (negati ve selection). BCD-F9 was found to be effective in mediating tumour cell ki lling in vitro by ADCC and ADCMC mechanisms. These results suggest that the mAb BCD-F9 can have it potential rise in immunotherapy for treatment of tu mours of different origin. (C) 2001 Elsevier Science Ltd. All rights reserv ed.